Table 2. Expression of S100A2 (n=114 sites: 101 non-neoplastic, normal and hyperplastic, and 13 preinvasive).
|
Nuclear |
Cytoplasmic |
|||
|---|---|---|---|---|
| Tumours | Negative | Positive | Negative | Positive |
| (A) Expression pattern of S100A2 across a series of 47 primary NSCLCsa | ||||
| Adenocarcinoma | 15 | 9 | 14 | 10 |
| Large cell | 1 | 1 | ||
| LCNEC | 2 | 2 | ||
| NSCLC undifferentiated | 1 | 1 | ||
| Squamous cell | 3 | 16 | 3 | 16 |
| Apical epithelial sites | |
|
||
| (B) Association of S100A2 expression of the apical part of the epithelium with histology (n=114 sites: 101 non-neoplastic, normal and hyperplastic, and 13 preinvasive)b | ||||
| Normal | 45 | 1 | 46 | 0 |
| Hyperplastic (goblet/basal) | 46 | 9 | 46 | 9 |
| Metaplasia/dysplasia/CIS | 5 | 8 | 7 | 6 |
a
While there was a strong bias towards positive staining in squamous cell carcinomas, a significant fraction of adenocarcinomas also strongly expressed the gene.
b
All histologically normal sites but one showed a consistent staining pattern of exclusively basal cell staining. Preneoplastic sites from individual patients showed strong expression. Apical cell staining was predominantly related to the histological state of the tissue and was not consistent for any patient across all non-neoplastic sites analysed.